HODGKIN LYMPHOMA

This study tested a stem cell transplant from half-matched (haploidentical) family donors for people with various blood cancers. The treatment used a reduced-intensity chemotherapy and radiation regimen to prepare the body for the transplant. The goal was to see how many patients…

This study tested a new drug combination (A+AVD) against the standard treatment (ABVD) for people with advanced Hodgkin lymphoma who had not been treated before. Over 1,300 participants were randomly assigned to one of the two treatments. The goal was to see which combination wor…

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with different types of blood cancers like lymphoma and leukemia. The main goal was to check safety and see how well the treatment works. This is an early-stage study, so results help gui…

This study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant could help keep lymphoma from coming back. It included 82 adults with Hodgkin or non-Hodgkin lymphoma that had returned or not responded to prior treatment. The main goal was to see…

This study tested two drugs—pembrolizumab and brentuximab vedotin—in 304 people whose Hodgkin lymphoma had returned or not responded to prior therapy. The goal was to see which drug better delays cancer growth and extends life. Participants received treatment for up to 35 cycles …

This study tested the safety of the drug nivolumab, alone or combined with other drugs like daratumumab, in 320 people with blood cancers (lymphoma or multiple myeloma) that had returned or stopped responding to treatment. The main goal was to track serious side effects. This is …

This study tested a new two-drug combination (MK-4280A) against standard chemotherapy in 203 people with classical Hodgkin lymphoma that had returned or stopped responding to prior treatments, including PD-(L)1 therapy. The goal was to see if the combination could help people liv…

This study tested a two-step stem cell transplant for 62 people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by a stem cell transplant. The goa…

This early-phase study tested a new drug combination (duvelisib plus BMS-986345) in 14 people with blood cancers like lymphoma, myeloma, or leukemia. The main goal was to find a safe dose and check for side effects. Researchers also looked at how well the cancer responded after 3…

This small pilot study tested whether an 8-week home exercise program guided by a trainer over video calls is practical and helpful for lymphoma survivors. The goal was to see if this approach could improve heart health in survivors who face a higher risk of cardiovascular proble…

This study looked at 1,753 patients needing a bone marrow transplant for blood cancers or other serious blood disorders. It compared two approaches: first searching for a matched unrelated donor, or going straight to an alternative donor (like a half-matched family member). The g…

This study tested a personalized geriatric optimization plan (GO!) in 30 patients aged 60 and older who were getting a stem cell transplant for blood cancers or bone marrow failure. The plan included tailored changes to diet, sleep, activity, and medications. The goal was to see …

This study looked at the genes of over 1,300 people with blood cancers like lymphoma, leukemia, and multiple myeloma. The goal was to find genetic patterns that could explain why some patients respond well to treatment while others do not. Researchers used stored tissue samples a…